Key facts
- The Nifty Pharma index has risen approximately 6% year-to-date, significantly outperforming other major Indian indices.
- Several Indian pharmaceutical companies, including Gland Pharma, Wockhardt, and Laurus Labs, have posted double-digit returns.
- Robust domestic demand for pharmaceutical products is a key driver of the sector's resilience.
- Global healthcare trends, such as ageing populations and increased spending, are expected to benefit the sector.
- Potential supply chain diversification away from China is creating new opportunities for Indian CDMOs.
Indian pharmaceutical stocks have demonstrated remarkable resilience and delivered strong returns, significantly outperforming broader market indices in the current year. The Nifty Pharma index has seen a gain of approximately 6% year-to-date, contrasting sharply with the Nifty's 11% decline, Nifty IT's 24% fall, and the around 8% drops in Nifty Bank and Nifty Auto.
This outperformance has occurred against a challenging global economic backdrop, marked by geopolitical tensions, tariff uncertainties, slowing corporate earnings, and concerns over global economic momentum. Despite these headwinds, several Indian pharma companies have achieved double-digit returns. As of June 9, Gland Pharma led the pack with a nearly 33% surge, followed by Wockhardt at 30%, Laurus Labs at 29%, Aurobindo Pharma at 22%, JB Chemicals and Zydus Life at 21% each, and Torrent Pharma at 16%.
A primary driver of this sector's strength is the robust growth in India's domestic formulations market. Kotak Equities reported that most large pharmaceutical companies experienced double-digit domestic growth in the March quarter, fueled by healthy demand across both chronic and acute therapies. This domestic focus provides stability, unlike export-oriented sectors vulnerable to global demand fluctuations and trade risks.
Looking ahead, brokerages maintain a positive outlook. Bernstein initiated coverage on six major pharma companies, favoring Zydus Lifesciences, Lupin, and Sun Pharma. The firm anticipates structural trends over the next decade, including ageing populations, increased healthcare spending, and AI-driven innovation, could expand India's biopharma industry to nearly $195 billion. AI adoption is also expected to enhance operational efficiency, potentially boosting profit margins by three to four percentage points.
Analysts suggest that despite the recent rally, valuations remain supportive. While sector valuations have slightly exceeded their 10-year average, they largely reflect domestic growth and challenges in the U.S. generic drug market. Opportunities in innovation, specialty products, and emerging markets may not be fully priced in. Kotak Equities noted that while the U.S. business faces pricing pressures, domestic, European, and other international markets continue to offer support.
The defensive nature of pharmaceutical companies has also made them attractive to investors seeking stable earnings visibility amidst broader market concerns. Unlike cyclical sectors, pharma companies offer predictable cash flows and are less sensitive to commodity price swings or shifts in consumer sentiment.
Furthermore, geopolitical developments involving China could present new opportunities. The U.S. Department of Defense's inclusion of Chinese companies like WuXi AppTec on a list linked to the Chinese military could encourage global pharmaceutical firms to diversify their supply chains away from China. While such shifts take time, Indian contract development and manufacturing organizations (CDMOs) like Divi's Laboratories, Laurus Labs, and Syngene are seen as potential beneficiaries.